Skip to main page content
Accesskeys
  • Page of 1
  1. Lesch BJ, Tothova Z, Morgan EA, Liao Z, Bronson RT, Ebert BL, Page DC. Intergenerational epigenetic inheritance of cancer susceptibility in mammals. eLife. 2019;
  2. Tothova Z, Krill-Burger JM, Popova KD, Landers CC, Sievers QL, Yudovich D, Belizaire R, Aster JC, Morgan EA, Tsherniak A, Ebert BL. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell. 2017 Oct 5;21(4):547-555.e8. doi: 10.1016/j.stem.2017.07.015. PubMed PMID: 28985529; PubMed Central PMCID: PMC5679060.
  3. Tothova Z, Ebert BL. Doubling Down on Mutant RAS Can MEK or Break Leukemia. Cell. 2017 Feb 23;168(5):749-750. doi: 10.1016/j.cell.2017.02.013. PubMed PMID: 28235190.
  4. Puram RV, Kowalczyk MS, de Boer CG, Schneider RK, Miller PG, McConkey M, Tothova Z, Tejero H, Heckl D, Järås M, Chen MC, Li H, Tamayo A, Cowley GS, Rozenblatt-Rosen O, Al-Shahrour F, Regev A, Ebert BL. Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell. 2016 Apr 7;165(2):303-16. doi: 10.1016/j.cell.2016.03.015. PubMed PMID: 27058663; PubMed Central PMCID: PMC4826477.
  5. Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally A. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov. 2016 Apr;6(4):368-81. doi: 10.1158/2159-8290.CD-15-1434. Epub 2016 Mar 7. PubMed PMID: 26951227; PubMed Central PMCID: PMC4851866.
  6. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016 Feb;34(2):184-191. doi: 10.1038/nbt.3437. Epub 2016 Jan 18. PubMed PMID: 26780180; PubMed Central PMCID: PMC4744125.
  7. Tothova Z, Berliner N. Hemophagocytic Syndrome and Critical Illness: New Insights into Diagnosis and Management. J Intensive Care Med. 2015 Oct;30(7):401-12. doi: 10.1177/0885066613517076. Epub 2014 Jan 8. Review. PubMed PMID: 24407034; PubMed Central PMCID: PMC4099298.
  8. Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ, Root DE. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol. 2014 Dec;32(12):1262-7. doi: 10.1038/nbt.3026. Epub 2014 Sep 3. PubMed PMID: 25184501; PubMed Central PMCID: PMC4262738.
  9. Tothova Z, Bradner JE. Anemia . In: Harrison’s Manual of Oncology. 2nd ed. Chabner BA, Longo DL, editors. United States: McGraw-Hill Education; 2014.
  10. Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Järås M, Puram R, Dancik V, Al-Shahrour F, Kindler T, Tothova Z, Chattopadhyay S, Hasaka T, Narayan R, Dai M, Huang C, Shterental S, Chu LP, Haydu JE, Shieh JH, Steensma DP, Munoz B, Bittker JA, Shamji AF, Clemons PA, Tolliday NJ, Carpenter AE, Gilliland DG, Stern AM, Moore MAS, Scadden DT, Schreiber SL, Ebert BL, Golub TR. Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol. 2013 Dec;9(12):840-848. doi: 10.1038/nchembio.1367. Epub 2013 Oct 27. PubMed PMID: 24161946; PubMed Central PMCID: PMC4009363.
  11. Tothova Z, Steensma DP, Ebert BL. New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Clin Cancer Res. 2013 Apr 1;19(7):1637-43. doi: 10.1158/1078-0432.CCR-12-1251. Epub 2013 Jan 17. Review. PubMed PMID: 23329810; PubMed Central PMCID: PMC3748432.
  12. Tothova Z, Wagner AJ. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors. Curr Opin Oncol. 2012 Jul;24(4):409-13. doi: 10.1097/CCO.0b013e328354c155. Review. PubMed PMID: 22664824.
  13. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Fröhling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011 Sep 2;146(5):697-708. doi: 10.1016/j.cell.2011.07.032. PubMed PMID: 21884932; PubMed Central PMCID: PMC3826540.
  14. Cornejo MG, Mabialah V, Sykes SM, Khandan T, Lo Celso C, Lopez CK, Rivera-Muñoz P, Rameau P, Tothova Z, Aster JC, DePinho RA, Scadden DT, Gilliland DG, Mercher T. Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. Blood. 2011 Aug 4;118(5):1264-73. doi: 10.1182/blood-2011-01-328567. Epub 2011 Jun 7. PubMed PMID: 21653327; PubMed Central PMCID: PMC3152494.
  15. Lee JY, Nakada D, Yilmaz OH, Tothova Z, Joseph NM, Lim MS, Gilliland DG, Morrison SJ. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell. 2010 Nov 5;7(5):593-605. doi: 10.1016/j.stem.2010.09.015. PubMed PMID: 21040901; PubMed Central PMCID: PMC2995996.
  16. Tothova Z, Gilliland DG. A radical bailout strategy for cancer stem cells. Cell Stem Cell. 2009 Mar 6;4(3):196-7. doi: 10.1016/j.stem.2009.02.008. PubMed PMID: 19265655.
  17. Lee BH, Tothova Z, Levine RL, Anderson K, Buza-Vidas N, Cullen DE, McDowell EP, Adelsperger J, Fröhling S, Huntly BJ, Beran M, Jacobsen SE, Gilliland DG. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell. 2007 Oct;12(4):367-80. doi: 10.1016/j.ccr.2007.08.031. PubMed PMID: 17936561; PubMed Central PMCID: PMC2104473.
  18. Tothova Z, Gilliland DG. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell. 2007 Aug 16;1(2):140-52. doi: 10.1016/j.stem.2007.07.017. Review. PubMed PMID: 18371346.
  19. Tothova Z, Mercher T. [FoxO: stress or eternal life]. Med Sci (Paris). 2007 May;23(5):466-7. doi: 10.1051/medsci/2007235466. PubMed PMID: 17502057.
  20. Klose RJ, Yan Q, Tothova Z, Yamane K, Erdjument-Bromage H, Tempst P, Gilliland DG, Zhang Y, Kaelin WG Jr. The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell. 2007 Mar 9;128(5):889-900. doi: 10.1016/j.cell.2007.02.013. Epub 2007 Feb 22. PubMed PMID: 17320163.
  21. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegué E, DePinho RA, Gilliland DG. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 2007 Jan 26;128(2):325-39. doi: 10.1016/j.cell.2007.01.003. PubMed PMID: 17254970.
  22. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH, DePinho RA. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007 Jan 26;128(2):309-23. doi: 10.1016/j.cell.2006.12.029. PubMed PMID: 17254969; PubMed Central PMCID: PMC1855089.
  23. Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z, Manola JB, Ganesan S, Lansdorp PM, Collins K, Hahn WC. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8222-7. doi: 10.1073/pnas.0503095102. Epub 2005 May 31. PubMed PMID: 15928077; PubMed Central PMCID: PMC1149439.
  24. Gu TL, Tothova Z, Scheijen B, Griffin JD, Gilliland DG, Sternberg DW. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood. 2004 Jun 15;103(12):4622-9. doi: 10.1182/blood-2003-03-0820. Epub 2004 Feb 12. PubMed PMID: 14962911.
  • Page of 1